Expression Profiling of Genes Associated with the Pathogenesis of Recurrent Laryngeal Papillomatosis
Molecular pathogenesis of RLP
DOI:
https://doi.org/10.53560/PPASB(61-sp1)1015Keywords:
Gene Expression Profiling, Human papillomavirus (HPV), Laryngeal Papillomatosis, Transoral Laser Microsurgery (TLM)Abstract
Recurrent Laryngeal Papillomatosis (RLP) affects the aero-digestive intersection with a predilection for the glottis. It is predominantly a juvenile-onset disease. The main infectious agents are type 6 and 11 low-risk human papillomaviruses. Understanding the genetic changes associated with the pathogenesis of RLP might prove helpful to mark the severity and aggression of the disease and lead to better clinical management. Clinically diagnosed RLP children below the age of 12 years along with a control sample of healthy tissue from age and gender-matched children undergoing tonsillectomy and thyroidectomy were collected. All the samples were processed for total RNA extraction followed by first strand cDNA synthesis. Real-time PCR was done to determine the relative gene expression of EGFR, ER-α, CXCL12, CXCR4, GLUT-1, IGF-1, HIF-1α, VEGF, ERK1/2, PI3K and AKT genes along with GAPDH as gene of reference. An increase in the transcriptional level expression of the genes CXCL12/CXCR4, GLUT-1, EGFR, ER-α, and IGF-I was observed in the cases in comparison to the controls. The expression of HIF-1α, VEGF, PI3K, and AKT genes was not noticeably elevated. The gene expression analysis may open the avenues for possible strategies that can be employed to treat RLP more effectively.
References
G.A. Rivera, F Morell. Laryngeal Papillomas. Treasure Island (FL). StatPearls Publishing Treasure Island, FL, USA (2023).
H.K. Kashima, T. Kessis, P. Mounts, and K. Shah. Polymerase chain reaction identification of human papillomavirus DNA in CO2
laser plume from recurrent respiratory papillomatosis. Otolaryngology–Head and Neck Surgery 104(2): 191-195 (1991).
M. Carifi, D. Napolitano, M. Morandi, and D. Dall’Olio. Recurrent respiratory papillomatosis: current and future perspectives. Therapeutics and Clinical Risk Management 11: 731-738 (2015).
C.S. Derkay. Recurrent Respiratory Papillomatosis. The Laryngoscope 111(1): 57-60 (2001).
E.Z. Saavedra, C.C. Chilet, J.M. Afaray, and M.L. Vilchez. Recurrent laryngeal papillomatosis with pulmonary involvement: case report. Revista Peruana de Medicina Experimental y Salud Pública 40(1): 111-114 (2023).
S.A. Ballestas, S. Shelly, R.M. Soriano, and A. Klein. Trends in recurrent respiratory papillomatosis treatment. Acta Otorrinolaringologica (English Edition) 72(2): 109-120 (2021).
T. Ilmarinen, J. Hagström, C. Haglund, E. Auvinen, I. Leivo, A. Pitkäranta, and L.M. Aaltonen. Low expression of nuclear Toll-like receptor 4 in laryngeal papillomas transforming into squamous cell carcinoma. Otolaryngology–Head and Neck Surgery 151(5): 785-90 (2014).
S. Mikolajczak, G. Quante, S. Weissenborn, A. Wafaisade, U. Wieland, J.C. Lüers, J.P. Klussmann, and D. Beutner. The impact of cidofovir treatment on viral loads in adult recurrent respiratory papillomatosis. European Archives of Oto-RhinoLaryngology 269: 2543–2548 (2012).
P.L. Rady, V.J. Schnadig, R.L. Weiss, T.K. Hughes, and S.K. Tyring. Malignant transformation of recurrent respiratory papillomatosis associated with integrated human papillomavirus type 11 DNA and mutation of p53. The Laryngoscope 108(5): 735-740 (1998).
K.J. Livak, and T.D. Schmittgen. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method.
Methods 25(4): 402-408 (2001).
M.M. Moldan, B.C. Bostrom, R.J. Tibesar, T.A. Lander, and J.D. Sidman. Epidermal growth factor receptor inhibitor therapy for recurrent respiratory papillomatosis. F1000Research 2: 202 (2013).
S. Logotheti, D. Papaevangeliou, I. Michalopoulos, M. Sideridou, K. Tsimaratou, I. Christodoulou, K. Pyrillou, V. Gorgoulis, S. Vlahopoulos, and V. Zoumpourlis. Progression of Mouse Skin Carcinogenesis Is Associated with Increased Erα Levels and Is Repressed by a Dominant Negative Form of Erα. PLoS One 7(8): e41957 (2012).
A.M. Brufsky, and M.N. Dickler. Estrogen receptorpositive breast cancer: exploiting signaling pathways implicated in endocrine resistance. The Oncologist 23(5): 528–539 (2018).
H. Xu, S. Yu, Q. Liu, X. Yuan, S. Mani, R.G. Pestell, and K. Wu. Recent advances of highly selective CDK4/6 inhibitors in breast cancer. Journal of Hematology & Oncology 10(1): 97 (2017).
L.K. Dunnwald, M.A. Rossing, and C.I. Li. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Research 9(1): R6 (2007).
F. Meuris, L. Carthagena, A.J. Ros, F. Gaudin, P. Cutolo, C. Deback, Y. Xue, F. Thierry, J. Doorbar, and F. Bachelerie. The CXCL12/CXCR4 Signaling Pathway: A New Susceptibility Factor in Human Papillomavirus. PLoS Pathogens 12(12): e1006039 (2016).
M. Mueckler, and B. Thorens. The SLC2 (GLUT) family of membrane transporters. Molecular Aspects of Medicine 34(2-3): 121–138 (2013).
L.Q. Chen, L. S. Cheung, L. Feng, W. Tanner, and W.B. Frommer. Transport of Sugars. Annual Review of Biochemistry 84: 865–894 (2015).
L. Feng, and W.B. Frommer. Structure and function of Semi SWEET and SWEET sugar transporters. Trends in Biochemical Sciences 40(8): 480–486 (2015).
D. Deng, and N. Yan. GLUT, SGLT, and SWEET: Structural and mechanistic investigations of the glucose transporters. Protein Science 25(3): 546–558 (2015).
A. Zambrano, M. Molt, E. Uribe, and M. Salas. Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy. International Journal of Molecular Sciences 20(13): 3374 (2019).
C. Fladeby, B. Bjønness, and G.S. Hanssen. GLUT1-mediated glucose transport and its regulation by IGF-I in cultured bovine chromaffin cells. Journal of Cellular Physiology 169(2): 242-247 (1996).
X. Tang, Q. Zhang, J. Nishitani, J. Brown, S. Shi, and A.D. Le. Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxiainducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clinical Cancer Research 13(9): 2568-2576 (2007).
C.A. Moody, and L.A. Laimins. Human papillomavirus oncoproteins: pathways to transformation. Nature Reviews Cancer 10(8): 550-
(2010).
J. Krieger, E. Sforza, M. Apprill, E. Lantpert, E. Weitzenblum, and J. Ratomaharv. Pulmonary hypertension, hypoxemia, and hypercapnia in obstructive sleep apnea patients. Chest 96(4): 729–737 (1989).
S. Budweiser, R.A. Jörres, and M. Pfeifer. Treatment of respiratory failure in COPD. International Journal of Chronic Obstructive Pulmonary Disease 3(4): 605–618 (2008).
A.C. Selfridge, M.A.S. Cavadas, C.C. Scholz, E.L. Campbell, L.C. Welch, E. Lecuona, S.P. Colgan, K.E. Barrett, P.H.S. Sporn, J.I. Sznajder, E.P. Cummins, and C.T. Taylor. Hypercapnia Suppresses the HIF-dependent Adaptive Response to Hypoxia. Journal of Biological Chemistry 291(22): 11800-11808 (2016).
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Upon acceptance of an article, its copyright will be assigned to the Pakistan Academy of Sciences.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY). Allows users to: copy the article and distribute; abstracts, create extracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation); include in a collective work (such as an anthology); and text or data mine the article. These uses are permitted even for commercial purposes, provided the user: includes a link to the license; indicates if changes were made; gives appropriate credit to the author(s) (with a link to the formal publication through the relevant DOI); and does not represent the author(s) as endorsing the adaptation of the article or modify the article in such a way as to damage the authors' honor or reputation.
